UNASSIGNED: @entity2033 ( @entity2033 ) @entity1 and @entity19 models show @entity73 even before the onset of motor symptoms. Deficits in hippocampal synaptic plasticity have been involved in the @entity2033 memory impairment. Several studies show that @entity1421 ( @entity1421 ) @entity17783 stimulates synaptic plasticity and memory formation. However, this role was not explored in @entity179 . Here, we investigated the capacity of @entity1421 @entity17783 to promote synaptic plasticity and memory improvements in a model of @entity2033 , the R6/1 @entity19 , by administration of the agonist @entity396 . We found that @entity396 increases dendritic branching in cultured hippocampal neurons in a @entity9140 ( @entity9140 )-dependent manner. Then, we implanted an osmotic mini-pump system to chronically administrate @entity396 to R6/1 @entity19 from 14 to 18weeks of age. We observed that @entity396 treatment ameliorates the R6/1 long-term @entity2414 as analyzed by the T-maze spontaneous alternation task and the novel object recognition test. Importantly, administration of @entity396 promoted the expression of hippocampal @entity9140 . Moreover, the treatment with @entity396 in R6/1 @entity19 blocked the reduction in the number of @entity39061 and @entity18358 positive particles observed in hippocampus of vehicle-R6/1 @entity19 . In addition, we observed an increase of @entity268 levels in the dentate   of WT and R6/1 @entity19 treated with @entity396 . Accordingly, we showed a reduction in the number of mutant @entity25864 nuclear inclusions in the dentate gyrus of R6/1 @entity19 . Altogether, these results suggest a putative therapeutic effect of @entity1421 @entity17783 in reducing @entity73 in @entity2033 .

XXXX EP2 activation reduces memory decline in R6/1 @entity19 model of @entity2033 by the induction of @entity9140 -dependent synaptic plasticity.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity9140 :: ('12064(Tax:10090)', 'Gene') :: ['BDNF', 'brain-derived neurotrophic factor'] @entity268 :: ('CHEBI:17489', 'Chemical') :: ['cAMP'] @entity39061 :: ('13385(Tax:10090)', 'Gene') :: ['PSD-95'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive deficits', 'learning and memory impairment'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE2', 'prostaglandin E2'] @entity396 :: ('MESH:D016595', 'Chemical') :: ['misoprostol'] @entity2033 :: ('MESH:D006816', 'Disease') :: ["Huntington's disease", 'HD'] @entity25864 :: ('15194(Tax:10090)', 'Gene') :: ['huntingtin'] @entity18358 :: ('72961(Tax:10090)', 'Gene') :: ['VGluT-1'] @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative diseases'] @entity17783 :: ('19217(Tax:10090)', 'Gene') :: ['EP2 receptor'] @entity2414 :: ('MESH:D008569', 'Disease') :: ['memory deficits']
@entity1421 :: (MESH:D015232,Chemical) :: ['Prostaglandin E2']
